ADUS

Good pond, adequate fish — with scale advantages over pure fragmented competitors. Addus is the largest publicly traded personal-care-focused provider, with entrenched Medicaid contract positions in high-density markets (Illinois, Texas, New Mexico) that smaller operators cannot easily replicate. The December 2024 Gentiva acquisition ($350M, ~$280M annualized revenue) transformed it from a regional operator into a true multi-state platform. It is not a monopolist — Aveanna and others compete for caregivers and contracts — and state Medicaid reimbursement policy remains the single biggest swing factor on revenue and margin.

Snapshot

What It Does

Addus HomeCare is the largest publicly traded provider of Medicaid personal-care services in the United States. Its caregivers visit elderly and disabled people at home to assist with activities of daily living — bathing, dressing, meals, medication reminders, mobility. This is not clinical nursing; it is non-medical personal care funded almost entirely by state Medicaid programmes and managed-care organisations (MCOs).

Three segments:

• Personal care (~77% of FY2025 revenue, ~$1.09B): Medicaid/MCO-funded home aides across ~25 states. Core business.
• Hospice (~18% of revenue): End-of-life comfort care, primarily Medicare-reimbursed.
• Home health (~5% of revenue): Medicare-certified skilled nursing and therapy visits. Smallest and currently declining organically.

Geographic footprint: Illinois (legacy core), Texas and Missouri (added via December 2024 Gentiva acquisition), New Mexico, Indiana (2026 entry), and ~20 additional states.

What It's Planning

Addus is executing a deliberate roll-up strategy in the fragmented personal-care market:

1. Gentiva integration (closed Dec 2024, $350M): Absorbing ~$280M annualised personal-care revenue across seven states — systems consolidation, EVV compliance roll-out, caregiver app deployment. FY2026 is the first full year with Gentiva on the books.
2. Indiana expansion: HomeCourt acquisition closed May 2026 (~$10M annualised revenue) with a second Indiana deal already under definitive agreement (~$9-10M annualised). Combined Indiana run-rate guided to 'just under $20M.'
3. Next Gentiva-scale deal: Management flagged two to three comparable opportunities ($250M+ annualised revenue) in the pipeline at Q1 2026. Balance sheet ($103M cash, net cash positive) is described as ready to move 'fairly rapidly.'
4. Margin expansion: Full-year FY2026 adj. EBITDA margin guided 'above 12%' (vs 9.74% EBIT in FY2025 — note adj. EBITDA adds back D&A and stock comp, so these are not directly comparable, but the direction is margin expansion).
5. Caregiver technology: New caregiver app deployed in Illinois, New Mexico, and Texas. 10%+ of Texas caregivers downloaded it within days of launch. Aimed at reducing turnover and improving scheduling.

Catalysts & Demand Drivers

Near-term:

• Q2 2026 Earnings (~early August 2026): First quarter with both Illinois (effective Jan 1, 2026) and Texas (effective Sept 2025) rate increases fully in the run rate. EPS beat in Q1 2026 ($1.62 adj. vs $1.55 est.); Q2 is the test of whether margin expansion is tracking toward the 12%+ adj. EBITDA target. A beat on both revenue and margin would likely reverse the Q1 sell-off.
• Second Indiana Acquisition Close (H2 2026): Definitive agreement already signed. Tuck-in deals at no incremental G&A confirm the roll-up machine is running beyond Gentiva.
• New Mexico HCBS $10M Funding (H2 2026, optionality): State allocated $10M for HCBS; implementation details still pending. Addus has meaningful NM presence. Not booked revenue — treat as upside optionality.
• Potential Gentiva-Scale Acquisition (2026-2027, optionality): Pipeline commentary only; no deal announced. Would be the highest-magnitude catalyst if executed at reasonable terms.
• CMS Medicaid Access Rule 80/20 Elimination (2026): Management expects elimination 'this year.' A relief event removing an overhang, not a growth catalyst per se.

Structural:

• Secular shift of Medicaid HCBS spending from institutions to home-based settings — bipartisan fiscal logic, active in Illinois, Texas, and most large Medicaid states.
• Fragmented personal-care market providing durable M&A runway — hundreds of small regional operators remain unconsolidated.

Track Record

Revenue (SEC XBRL verified):

3-year growth FY2022–FY2025: +49.6% (not 34% as sometimes stated — the verified XBRL figure is 49.6%).

Profitability (SEC XBRL verified):

Operating income grew +101.7% FY2022 to FY2025. Net income grew +108.4% over the same period. Both figures SEC XBRL confirmed.

Operating cash flow (SEC XBRL verified):

OCF declined $4.9M YoY in FY2025 despite revenue +23.2% and net income +30.4% — Gentiva working-capital absorption is the most likely cause. The 116% OCF/net income conversion ratio is still healthy but directionally weaker. This warrants monitoring in FY2026.

Balance sheet:

• Cash (FY2024 year-end): $98.9M (SEC XBRL)
• Cash (Q1 2026, 10-Q): $103M
• Bank debt (Q1 2026, 10-Q): $94.3M — net cash positive
• After spending $350M on Gentiva (Dec 2024), the company rebuilt its cash position and reduced debt — a strong signal of underlying cash generation.

Share count / dilution (SEC XBRL verified):

FY2024 saw a +11.8% single-year increase (Gentiva equity financing). Total dilution since 2010: +73.6%. The roll-up model structurally relies on periodic equity issuance; the next Gentiva-scale deal should be expected to dilute by another ~10-12% if the Gentiva precedent holds.

Valuation

Trailing P/E: $1,711M market cap / $95.9M FY2025 net income = ~17.8x

For context:

• Net income grew 108% over three years (FY2022 $46M → FY2025 $95.9M, XBRL confirmed)
• Healthcare services peers typically trade 20–30x earnings when growth is clean
• The discount reflects thin margins (~9.74% EBIT), government-payer concentration (~87%), and live Medicaid legislative risk
• Barclays (Underweight) has a $92 target — essentially at market — representing the bear floor
• Sell-side consensus range: $127–$135 (bull case, clean integration + rate cycle)

Fair-value range: $97–$117

Method: FY2026 net income estimated at $110–$120M, based on (a) organic same-store growth ~6% on FY2025 $1.42B base reaching ~$1.51B revenue, (b) EBIT margin trending toward the 12%+ adj. EBITDA guidance, and (c) $35.2M annualised rate-increase revenue fully embedded from Q2 2026. Applied 17–18.3x P/E (consistent with FY2025 trailing multiple, reflecting unchanged risk profile). At 18.7M shares: low end $110M × 17.8x / 18.7M = ~$105/share; high end $120M × 18.3x / 18.7M = ~$117/share. Floor anchored by Barclays $92 bear case. No M&A upside modelled. A Gentiva-scale acquisition in 2026-2027 at a reasonable multiple represents incremental upside not captured in this range but would also add ~10-12% dilution.

Ownership & Insiders

No dividends. No buybacks. All free cash flow and balance sheet capacity is deployed into acquisitions. The Gentiva deal ($350M, Dec 2024) was the largest in company history and was partly equity-funded — adding 1.9M shares (+11.8%) in a single year.

Short interest: ~6.5% of float as of February 2026, up 23.5% from late January and up 42.1% over 12 months. This is not alarming (not heavily shorted) but the trend is upward, consistent with bears positioning on Medicaid risk and home health payment rule uncertainty.

Institutional ownership is standard for a profitable NASDAQ-listed company of this size. No unusual insider selling pattern detected. The stock declined ~3% in premarket after Q1 2026 earnings despite an EPS beat — indicating the market is efficiently pricing execution risk, not a promotional name.

Bull Case

Addus is the largest publicly traded Medicaid personal-care provider trading at ~17.8x trailing net income on a decade of unbroken compounding: revenue 3.5x from FY2016 to FY2025 (XBRL: $401M to $1.42B), operating income from $15.5M to $138.6M, net income from $12.2M to $95.9M.

The structural demand driver — aging demographics + home care costs less than nursing homes — is bipartisan and mathematically durable. The $35.2M annualised rate-increase revenue (Illinois + Texas, confirmed via press release) is not yet fully in the FY2025 trailing numbers used to price the stock. Q1 2026 already showed adj. EPS $1.62 beating $1.55 estimates; Q2 2026 will be the first quarter where both rate increases are simultaneously fully embedded.

The balance sheet (net cash positive, $103M cash as of Q1 2026) is primed for the next acquisition. Management has explicitly flagged two to three Gentiva-scale targets — at ~$250M+ annualised revenue each, one deal would add ~17% to the FY2025 revenue base before integration synergies. Same-store personal-care growth of 6.5% in Q1 2026 confirms the organic engine is running independently of M&A. At $91.68, the stock is near the Barclays bear-case floor despite an EPS beat — offering a potential entry if federal Medicaid risk does not materialise in its worst form.

Bear Case & Red Flags

Medicaid concentration — existential single-factor dependency (HIGH severity): ~87% of revenue is government-funded; all personal-care pricing is set annually by state legislatures. A 5% rate cut on the ~$1.09B personal-care segment would erase ~$54M of revenue against a largely fixed cost base — approximately 39% of FY2025 operating income. The 'One Big Beautiful Bill' federal budget reconciliation could impose per-capita caps or block grants on Medicaid; any resulting state budget pressure flows directly to HCBS reimbursement rates. The CEO named this the #1 concern for 2026.

Caregiver labor shortage permanently compresses net rate benefit (HIGH severity): Industry-wide caregiver turnover runs ~77-79% annually. Addus is hiring ~108 caregivers per business day just to hold census. Tighter immigration enforcement in 2025-2026 has deepened the structural supply gap. Rate increases are partially or fully passed through to caregiver wages to remain competitive — the net margin benefit is materially less than the gross rate increment. FY2025 OCF declined $4.9M despite revenue +23.2%, consistent with labor cost absorption outpacing revenue growth at the margin.

Gentiva integration goodwill and execution risk (MEDIUM severity): $350M acquisition of a personal-care business (asset-light) generates substantial goodwill on the balance sheet. The Q1 2026 revenue miss (vs. consensus) and hospice length-of-stay compression (25 → 23 days) suggest the acquired hospice book is not performing as initially modelled. Integration friction — MCO contract renegotiation in new states, EVV system roll-out, caregiver retention across seven added states — is a real execution risk throughout FY2026.

Home health organic decline and hospice margin compression (MEDIUM severity): Home health organic revenue declined 6.6% YoY in Q1 2026 (Medicare-reimbursed, subject to unfavourable CMS annual payment rules). Hospice ADC grew 8.2% to 3,804 but average length of stay declined from ~25 to ~23 days, compressing per-patient revenue. These two higher-margin Medicare segments (~23% of revenue combined) are both under pressure simultaneously.

Geographic and payer concentration (MEDIUM severity): Illinois and Texas together likely account for a disproportionate share of personal-care revenue (the $35.2M combined rate increase represents ~25% of FY2025 EBIT). Illinois has one of the worst pension-liability-to-GDP ratios of any US state and has experienced multi-year budget impasses (2015-2017). A future Illinois fiscal crisis could delay or reduce Medicaid reimbursement.

Share dilution and M&A dependency (LOW-MEDIUM severity): The roll-up model requires recurring equity issuance to fund acquisitions. +73.6% share dilution over 15 years (10.75M shares in 2010 → 18.67M in 2026, XBRL confirmed); +11.8% in FY2024 alone for Gentiva. A next Gentiva-scale deal would add another ~10-12% dilution or take leverage to ~2.5-3x EBITDA. EPS growth must outpace share issuance for per-share value to accrete — it has so far, but the margin is thin.

Regulatory and compliance exposure (MEDIUM severity): The CEO identified fraud crackdown as the #2 concern for 2026. Post-payment audits and retrospective reviews of personal-care claims are increasing. Newly absorbed Gentiva operations may carry compliance legacy risk from their prior ownership. A CMS or OIG audit demand in a major state could generate receivables clawbacks.

Interesting Findings

• The stock fell ~3% on Q1 2026 earnings despite beating EPS by $0.07 — the market is penalising the revenue miss and watching the top line closely. A second consecutive revenue miss in Q2 could push the stock toward or below the Barclays $92 target.
• Short interest is up 42.1% over 12 months as of February 2026. Bears appear positioned specifically on Medicaid reimbursement and home health payment rule uncertainty — not on business quality, which is generally acknowledged as sound.
• The fraud enforcement dynamic is a double-edged sword: if CMS and state Medicaid agencies successfully drive fraudulent operators out of the personal-care market, those patients and Medicaid dollars flow to compliant operators like Addus — a potential market-share gain that is not in any model.
• Addus's OCF/net income conversion ratio fell from 179% (FY2023) to 116% (FY2025) — still healthy, but a three-year compression trend worth monitoring. If it continues toward 1x or below, the roll-up thesis becomes harder to justify on a free-cash-flow basis.
• The company has been consistently profitable every year since at least FY2012 (the earliest net income in the XBRL series, aside from a single $1.98M loss in FY2011 likely from an acquisition charge). This is a genuine track record, not cyclical profitability.

The Read

Addus HomeCare is a genuinely well-run business in a structurally growing market, with a decade of verified compounding and a balance sheet that has survived a $350M acquisition while remaining net cash positive. At ~17.8x trailing earnings, it is not obviously cheap or expensive — it is priced for continued execution with no material reimbursement disruption.

The bull case is straightforward: aging demographics and the cost logic of home care are durable, rate increases are confirmed and compounding into the run rate, and the roll-up pipeline is explicitly funded and staffed. The bear case is equally straightforward: 87% government-payer concentration with no pricing power, a 9.74% EBIT margin that is vulnerable to any adverse rate cycle, and a live federal Medicaid block-grant debate that management itself calls the #1 risk.

What makes this a YELLOW rather than GREEN is not the business quality — the numbers are good — but the structural exposure to a single policy outcome (Medicaid funding) that is currently politically contested and outside management's control. The Barclays $92 bear target sitting essentially at market is the honest floor: if the 'One Big Beautiful Bill' passes with per-capita caps, the stock re-rates down regardless of execution quality. If it fails or phases in slowly, the organic compounding story reasserts and the $107 midpoint fair-value case is achievable within 12-18 months.

This is a business to understand deeply before the Q2 2026 earnings report (~early August 2026). That quarter will be the first clean read on whether the rate-increase tailwind is converting to margin expansion as guided — or whether labor cost pass-through and hospice weakness are absorbing the incremental revenue.

Research, not investment advice. Figures sourced from SEC filings and public data; verify before acting.